US 11,814,389 B2
Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Zhiwei Wang, Beijing (CN); Yunhang Guo, Beijing (CN); and Gongyin Shi, Beijing (CN)
Assigned to BEIGENE SWITZERLAND GMBH, Basel (CH)
Filed by BEIGENE SWITZERLAND GMBH, Basel (CH)
Filed on Jul. 6, 2022, as Appl. No. 17/858,827.
Application 17/858,827 is a continuation of application No. 17/146,855, filed on Jan. 12, 2021.
Application 17/146,855 is a continuation of application No. 16/325,447, granted, now 10,927,117, issued on Feb. 23, 2021, previously published as PCT/IB2017/054955, filed on Aug. 15, 2017.
Prior Publication US 2022/0340584 A1, Oct. 27, 2022
Int. Cl. C07D 487/04 (2006.01); A61P 35/02 (2006.01); A61P 35/04 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 35/02 (2018.01); A61P 35/04 (2018.01); C07B 2200/13 (2013.01)] 8 Claims
 
1. A composition comprising:
(i) a solid amorphous form of Compound 1,

OG Complex Work Unit Chemistry
wherein the solid amorphous form has:
(a) a mid-point temperature of a glass transition temperature of about 79.7° C.; and
(b) an enantiomeric excess value of at least 97%; and
(ii) a crystalline form of Compound 1, wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 16.4±0.2° and 21.4±0.2°.